An overview of visceral leishmaniasis elimination program in India: a picture imperfect

References

• Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ 1998;76(Suppl 2):23-5
   Google Scholar
• Narain JP. Eradicating and eliminating infectious diseases: past, Present and Future. Indian J Public Health 2011;55:81-7
   PubMedGoogle Scholar
• Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007;5:873-82
   PubMed Web of Science ®Google Scholar
• Alvar J, Vélez ID, Bern C, et al. WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7(5):e35671
   PubMed Web of Science ®Google Scholar
• WHO. Elimination of Kala-azar. Report of the Fourth Meeting of the Regional Technical Advisory Group (RTAG); 12–14 July 2011, Kathmandu, Nepal
   Google Scholar
• Bhattacharya SK, Sur D, Sinha PK, Karbwang J. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable. Indian J Med Res 2006;123:195-6
   PubMed Web of Science ®Google Scholar
• WHO. Leishmaniasis: number of cases of visceral leishmaniasis reported Data by country. Available from: http://apps.who.int/gho/data/node.main.NTDLEISHVNUM?lang=en [Last accessed 2 April 2014]
   Google Scholar
• Joshi A, Narain JP, Prasittisuk C, et al. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis 2008;45:105-11
   PubMedGoogle Scholar
• Ostyn B, Gidwani K, Khanal B, et al. Incidence of Symptomatic and Asymptomatic Leishmania donovani Infections in High-Endemic Foci in India and Nepal: a Prospective Study. PLoS Negl Trop Dis 2011;5:e1284
   PubMed Web of Science ®Google Scholar
• Topno RK, Das VN, Ranjan A, et al. Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in bihar, India. Am J Trop Med Hyg 2010;83:502-6
   PubMed Web of Science ®Google Scholar
• National Vector Borne Disease Control Programme. Kala-azar Cases and Deaths in the Country since 2008. Available from: www.nvbdcp.gov.in/ka-cd.html [Last accessed 2 April 2014]
   Google Scholar
• Directorate general of Health Services MOHFW. National vector born disease control programme. New Delhi. Government of India. Available from: http://nvbdcp.gov.in/kala-azar.html [Last accessed 2 April 2014
   Google Scholar
• National Health Policy. Department of Health, Ministry of Health and Family Welfare, Government of India, New Delhi. 2002. Available from: http://mohfw.nic.in [Last accessed on 2 April 2014]
   Google Scholar
• WHO. Regional Strategic Framework for elimination of kala-azar from the South-East Asia Region. (2011-2015). 2005. Available from: http://apps.searo.who.int/pds_docs/B4870.pdf [Last accessed 2 April 2014]
   Google Scholar
• WHO, Indicators for monitoring and evaluation of the kala-azar elimination programme, 2010. Available from: www.who.int/tdr/publications/documents/kala_azar_indicators.pdf [Last accessed 2 April 2014]
   Google Scholar
• Picado A, Das ML, Kumar V, et al. Phlebotomus argentipes seasonal patterns in India and Nepal. J Med Entomol 2010;47:283-6
   PubMedGoogle Scholar
• Department of National Vector Borne Disease Control Programme (a) Guidelines on vector control in kala-azar elimination. New Delhi. Available from: http://nvbdcp.gov.in/Doc/Guidelines-Vector-Control-KA-Elimination-FINAL.pdf [Last accessed 2 April 2014]
   Google Scholar
• WHO. Elimination of Kala-azar. Report of the Fourth Meeting of the Regional Technical Advisory Group (RTAG) Kathmandu, Nepal, 12 - 14 July 2011. Available from: http://apps.searo.who.int/pds_docs/B4811.pdf [Last accessed 2 April 2014]
   Google Scholar
• Dinesh DS, Das ML, Picado A, et al. Insecticide susceptibility of Phlebotomus argentipes in visceral leishmaniasis endemic districts in India and Nepal. PLoS Negl Trop Dis 2010;4(10):e859
   Google Scholar
• Singh RK, Mittal PK, Dhiman RC. Insecticide susceptibility status of Phlebotomus argentipes, a vector of visceral leishmaniasis in different foci in three states of India. J Vector Borne Dis 2012;49(4):254-7
   PubMedGoogle Scholar
• Joshi AB, Das ML, Akhter S. Chemical and environmental vector control as a contribution to the elimination of visceral leishmaniasis on the Indian subcontinent: cluster randomized controlled trials in Bangladesh, India and Nepal. BMC Med 2009;7:54
   PubMedGoogle Scholar
• Picado A, Singh SP, Rijal S, et al. Long-lasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ 2010;341:c6760
   PubMedGoogle Scholar
• Picado A, Singh SP, Vanlerberghe V, et al. Residual activity and integrity of PermaNet® 2.0 after 24 months of household use in a community randomised trial of long lasting insecticidal nets against visceral leishmaniasis in India and Nepal. Trans R Soc Trop Med Hyg 2012;106(3):150-9
   PubMedGoogle Scholar
• Ranjan A, Sur D, Singh VP, et al. Risk factors for Indian Kala-Azar. Am J Trop Med Hyg 2005;73:74-8
   PubMed Web of Science ®Google Scholar
• Kumar V, Kesari SK, Sinha NK, et al. Field trial of an ecological approach for the control of Phlebotomus argentipes using mud and lime plaster. Indian J Med Res 1995;101:154-6
   PubMed Web of Science ®Google Scholar
• Ostyn B, Vanlerberghe V, Picado A, et al. Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop Med Int Health 2008;13:1073-85
   PubMed Web of Science ®Google Scholar
• Das M, Banjara MR, Chowdhury R, et al. Visceral leishmaniasis on the Indian sub-continent: a multi-centre study of the costs of three interventions for the control of the sand fly vector, Phlebotomus argentipes. Ann Trop Med Parasitol 2008;102:729-41
   PubMed Web of Science ®Google Scholar
• WHO. WHO technical report series, 975. Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis. 2012
   Google Scholar
• Department of National Vector Borne Disease Control Programme (b). Diagnosis and treatment. New Delhi. Available at http://nvbdcp.gov.in/doc/guidelines-diagnosis-treatment-ka.pdf [Last accessed 2 April] [2014]
   Google Scholar
• Boelaert M, Rijal S, Regmi S, et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg 2004;70(1):72-7
   PubMedGoogle Scholar
• Government of India. Report of Expert Team on kala-azar programme assessment, New Delhi: Directorate of National Malaria Eradication Programme. 1991
   Google Scholar
• WHO. Annex 6. Costs of medicines in current use for the treatment of leishmaniasis. Available from: www.who.int/leishmaniasis/research/978_92_4_12_949_6_Annex6.pdf [Last accessed 2 April 2014]
   Google Scholar
• Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002;15:593-8
   PubMed Web of Science ®Google Scholar
• Sunder S. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 2007;3:733-40
   PubMedGoogle Scholar
• Rai K, Cuypers B, Bhattarai NR, et al. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain. MBio 2013;4:e00611-13
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362:504-12
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, et al. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. Trop Med Int Health 2008;13(9):1208-12
   PubMedGoogle Scholar
• Sundar S, Singh A, Agarwal D, et al. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am J Trop Med Hyg 2009;80(5):700-3
   PubMedGoogle Scholar
• Khamesipour A, Rafati S, Davoudi N, et al. Leishmaniasis vaccine candidates for development: a Global Overview. Indian J Med Res 2006;123:423-38
   PubMed Web of Science ®Google Scholar
• WHO. Leishmaniasis program. Available from: www.who.int/leishmaniasis/en/[Last accessed 2 April 2014]
   Google Scholar
• WHO. Post-kala-azar dermal leishmaniasis: a manual for case management and control. Report of a WHO consultative meeting; 2–3 July 2012; Kolkata, India. Available at http://apps.who.int/iris/bitstream/10665/78608/1/9789241505215_eng.pdf [Last accessed 2 April 2014]
   Google Scholar
• Médecins Sans Frontières. Briefing note. December 2011. Available from: www.msfaccess.org/sites/default/files/MSF_assets/NegDis/Docs/NegDis_KalaAzar_HIV_Briefing_DoubleBurden_ENG_2011.pdf [Last accessed 2 April 2014]
   Google Scholar
• Li XX, Zhou XN. Co-infection of tuberculosis and parasitic diseases in humans: a systematic review. Parasit Vectors 2013;6:79
   PubMed Web of Science ®Google Scholar
• Mondal D, Singh SP, Kumar N, et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 2009;3:e355
   PubMed Web of Science ®Google Scholar